Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.48 |
| ▸ | GRM1 | Q13255 | 8/20 | 0.45 |
| ▸ | GRM5 | P41594 | 7/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
| ▸ | GABRD | O14764 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.40 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651891 | 1.00 | PDK4 (0.48) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL31639892 | 0.92 | PDK4 (0.49) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL3817588 | 0.90 | PDK4 (0.49) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL18843609 | 0.87 | PDK4 (0.47) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL29661274 | 0.87 | PDK4 (0.47) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL30180163 | 0.86 | PDK4 (0.45) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL21169785 | 0.85 | PDK4 (0.46) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL28352523 | 0.85 | ADAM10 (0.38) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1545479 | 0.84 | PDK4 (0.47) | PDK4GRM1GRM5HTR6JAK1 | |
| SCHEMBL29651909 | 0.84 | PDK4 (0.47) | PDK4GRM1GRM5HTR6JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4011376-B1 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | ASCENTAGE PHARMA SUZHOU CO LTD (CN) | 2025-04-30 | — | — | EP | disclosed |
| EP-4446320-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | Oncobix Co., Ltd. (KR) | 2024-10-16 | — | — | EP | disclosed |
| CN-115043821-B | Aminopyrimidines as ALK inhibitors | 密歇根大学董事会 | 2024-08-06 | — | — | CN | disclosed |
| CN-118355012-A | Novel heterocyclic substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect and pharmaceutical composition containing the same | 昂科比克斯有限公司 | 2024-07-16 | — | — | CN | disclosed |
| WO-2023106881-A1 | NOVEL HETEROCYCLIC-SUBSTITUTED PYRIMIDINE DERIVATIVE EXHIBITING CANCER CELL GROWTH INHIBITORY EFFECT, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사 온코빅스 | 2023-06-15 | — | — | WO | disclosed |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-10-25 | — | — | US | disclosed |
| EP-4011376-A2 | COMBINATION OF AN ALK INHIBITOR AND AN EGFR INHIBITOR FOR TREATING CANCER | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-15 | — | — | EP | disclosed |
| EP-4001273-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-4001273-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | The Regents Of The University Of Michigan (US) | 2022-05-25 | — | — | EP | disclosed |
| US-20210330669-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROSI INHIBITOR AND EGFR INHIBITOR | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-10-28 | — | — | US | disclosed |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-07-14 | — | — | US | disclosed |
| EP-3504203-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | The Regents of The University of Michigan (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | UNIV MICHIGAN REGENTS (US) | 2019-06-13 | — | — | US | disclosed |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | BEIJING PEARL BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2018-07-17 | — | — | US | disclosed |
| WO-2018044767-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-08 | — | — | WO | disclosed |
| WO-2018044767-A2 | AMINOPYRIMIDINES AS ALK INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | SHANGHAI EMERALD WELLCARES PHARMACEUTICAL CO., LTD (CN) | 2017-08-31 | — | — | US | disclosed |
| EP-3150592-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | Beijing Pearl Biotechnology Limited Liability Company (CN) | 2017-04-05 | — | — | EP | disclosed |
| WO-2015180685-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USE THEREOF | 北京浦润奥生物科技有限责任公司 | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247392-A1 | ALK KINASE INHIBITOR, AND PREPARATION METHOD AND USES THEREOF | ALK, BRAF, ABL1 | PDK4 1223/4885GRM1 2849/4885GRM5 3511/4885 |
| US-20210330669-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF FAK/ALK/ROSI INHIBITOR AND EGFR INHIBITOR | ROS1, ALK, PTK2 | PDK4 3165/4885GRM1 1524/4885GRM5 2679/4885 |
| US-10023593-B2 | ALK kinase inhibitor, and preparation method and uses thereof | ALK, BRAF, ABL1 | PDK4 1223/4885GRM1 2849/4885GRM5 3511/4885 |
| US-11478477-B2 | Method for treating cancer by combination of FAK/ALK/ROS1 inhibitor and EGFR inhibitor | ROS1, ALK, PTK2 | PDK4 3066/4885GRM1 1355/4885GRM5 2640/4885 |
| US-20190175595-A1 | AMINOPYRIMIDINES AS ALK INHIBITORS | ALK, RET, BRAF | PDK4 1141/4885GRM1 2358/4885GRM5 3049/4885 |
| US-10709705-B2 | Aminopyrimidines as ALK inhibitors | ALK, RET, BRAF | PDK4 1141/4885GRM1 2358/4885GRM5 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.